Top Companies in the Intranasal Drug Delivery Devices Market
- MetLife, Inc.
- Prudential Financial, Inc.
- Manulife Financial Corporation
- Sun Life Financial
- AIA Group Limited
- AXA S.A.
- Allianz SE
- Aviva plc
- Legal & General Group
- Zurich Insurance Group
- Nippon Life Insurance
- Dai-ichi Life Holdings
- New York Life Insurance Company
- Northwestern Mutual Life Insurance
- MassMutual (Massachusetts Mutual Life Insurance Company)
- Guardian Life Insurance Company
- China Life Insurance Company
- Ping An Insurance Group
- HDFC Life Insurance (India)
- LIC (Life Insurance Corporation of India)
Market Growth
The global intranasal drug delivery devices market size is estimated at US$ 1.74 billion in 2024, is projected to grow to US$ 1.91 billion in 2025, and is expected to reach around US$ 4.54 billion by 2034. The market is projected to expand at a CAGR of 10.04% between 2025 and 2034.
Intranasal Drug Delivery Devices Market Trends
Increasing advancement in intranasal drug delivery devices with a focus on enhancing nose-to-brain delivery for systemic, local, and central nervous system diseases by application of nanotechnology, which contributes to the growth of the market.
For instance,
- In November 2025, Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC. This technology is emerging as a promising pathway to deliver new drugs to the brain to treat diseases of the central nervous system (CNS).
Increasing collaboration between the research institute and healthcare organization, which drives the growth of the market.
For Instance,
- In June 2025, Kindeva, a global CDMO and drug delivery expert, and Rocket Science Health (RSH), a Canadian technology healthcare company, joined forces to find partners to develop a new intranasal delivery platform. RSH’s cutting-edge technology, combined with Kindeva’s CDMO capabilities, will supercharge the product journey as RSH prepares for commercial readiness.
Intranasal Drug Delivery Devices Market – Value Chain Analysis
R&D
The number of factors considered during R&D of intranasal drug delivery devices, such as moisture sensitivity, solubility, particle size, particle shape, and flow characteristics, will affect deposition and rate of absorption.
Key Players: OptiNose, Inc. and Nemera Development S.A
Clinical Trials
Clinical trials of intranasal drug delivery include feasibility/pilot trials, safety trials, efficacy trials, and post-market trials.
Key Players: Clinipace and Parexel
Patient Support and Services
This device has been used in academic studies to deliver, for example, a topical steroid in patients with chronic rhinosinusitis and in a vaccine study.
Key Players: AptarGroup, Inc. and Kurve Technology, Inc.
Latest Announcements by Industry Leaders
In August 2025, Joris Silon, US Country President and Senior Vice President, stated, “The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers. FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected.”
Recent Developments in the Intranasal Drug Delivery Devices Market
- In July 2025, Aptar announced that its nasal drug delivery system was used in a recently published brain imaging study from Wake Forest University School of Medicine. According to the university’s press release, the “groundbreaking” study confirms a vital step toward new Alzheimer’s treatments: intranasal insulin, delivered via nasal spray, safely and effectively reaches key memory regions of the brain in older adults.
- In January 2025, Lonza announced a collaboration with Iconovo, a Swedish company specializing in developing inhalable drugs based on proprietary inhalers and dry powder formulations, to develop spray-dried formulations of an intranasal biologic that will be used in Iconovo’s proprietary intranasal device, ICOone Nasal.
- In September 2025, Strides Pharma Science Ltd announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc., a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).
- In October 2024, Aero Pump and Resyca are proud to announce their collaboration in the launch of the innovative Ultra Soft Nasal Pump Spray. Available for licensing immediately, this co-developed system represents a new frontier in nasal drug delivery, offering enhanced delivery efficiency, precision, and comfort for users.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
